Context Therapeutics Inc. (CNTX) stock
Close on Nov 12, 2026Market cap $18.19MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $18.19M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.59
- Dividend yield
- –
- Free cash flow yield
- -187.04%
Fundamentals
- Net income
- -$43.89M
- EPS, diluted
- -$0.46
- Free cash flow
- -$34.03M
- Book value per share
- $0.33
- Diluted shares
- 95M
Trading
- Previous close
- $0.22
- Open
- $0.21
- Day's range
- $0.20 – $0.21
- Volume
- 529,172
- Average volume (20 days)
- 1,536,840
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.29
- 52-week range
- $0.18 – $3.62
- RSI (14 days)
- 38.0
- Volatility (1 year)
- 104.6%
- Relative volume
- 0.30×
- WACC
- 11.3%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CNTX | S&P 500 | Difference | CNTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -35.1% | -2.7% | −32.4 pts | ||
| 3 months | -57.9% | -1.7% | −56.1 pts | ||
| Year to date | -86.5% | +11.9% | −98.4 pts | ||
| 1 year | -83.2% | +12.0% | −95.2 pts | ||
| 3 years | -81.4% | +78.2% | −159.6 pts | -42.9% | +21.2% |
| 5 years | -96.3% | +73.2% | −169.6 pts | -48.4% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Context Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Context Therapeutics
Pharmaceutical Preparations
Context Therapeutics is a clinical-stage biopharmaceutical company that advances T cell engaging bispecific antibody therapeutics for the treatment of solid tumors. Its drug development pipeline targets patient populations with unmet oncology needs, including gynecologic, testicular, bladder, lung, colon, and breast cancers. The company's lead investigational drug candidates include CTIM-76, CT-95, and CT-202, which direct immune responses against specific tumor-associated antigens such as Claudin 6, Mesothelin, and Nectin-4. Because Context Therapeutics remains in clinical development, it has not brought commercial products to market.
Company profile, executives and historyContext Therapeutics stock: common questions
What is Context Therapeutics's stock price?
CNTX closed at $0.20 on Nov 12, 2026, down 8.38% on the day. Over the past 52 weeks it traded between $0.18 and $3.62.
What is Context Therapeutics's market cap?
Context Therapeutics was worth $18.19M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CNTX's P/E ratio?
Context Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.46), so it has no meaningful P/E ratio.
Does Context Therapeutics pay a dividend?
No. Context Therapeutics has not paid a cash dividend over the last twelve months.
How has CNTX stock performed over the past year?
Including dividends, CNTX returned -83.2% over the past year, against +12.0% for the S&P 500.
How many CNTX shares are sold short?
5M shares were sold short at the latest FINRA report, 5.21% of the float, or 3.7 days of average trading volume.
Who are Context Therapeutics's competitors?
Companies most similar to Context Therapeutics by business, industry and size include CRVS, PLRX, CRBP, WHWK, NXTC.
See a number that looks wrong?